Literature DB >> 20019161

Intrinsic versus idiosyncratic drug-induced hepatotoxicity--two villains or one?

Robert A Roth1, Patricia E Ganey.   

Abstract

"Intrinsic" and "idiosyncratic" drug-induced liver injury reactions are commonly thought to arise by different modes of action. Intrinsic toxicity is reproducible in animals and occurs dose-dependently at sublethal doses. Environmental and genetic sensitivity factors can influence the toxicity of intrinsic hepatotoxicants. Among these is inflammatory stress. For example, exposure of mice to inflammatory bacterial lipopolysaccharide (LPS) causes a leftward shift in the dose-response relationship for acetaminophen hepatotoxicity; that is, acetaminophen toxicity is enhanced by LPS-induced inflammatory stress. Idiosyncratic reactions present themselves very differently than intrinsic ones; they happen in a minority of patients, with variable time of onset and no obvious relationship to drug dose, and they are not reproducible in usual animal tests. Although these characteristics seem to distinguish them from intrinsic reactions, consideration of fundamental principles of dose response can explain the differences. For a drug that causes idiosyncratic hepatotoxicity, the liver may not be a typical target for toxicity because the dose-response curve for hepatotoxicity lies to the right of the lethal dose. However, a sporadically occurring sensitivity factor, such as an inflammatory episode, could shift the dose-response curve for hepatotoxicity to the left, thereby bringing hepatotoxic doses into the therapeutic range. This hypothesis can account for the bizarre characteristics of idiosyncratic reactions and is supported by recent results showing that several drugs associated with human idiosyncratic reactions can be rendered hepatotoxic to rodents upon interaction with an inflammatory stimulus. In light of this view, intrinsic and idiosyncratic reactions may not be that different after all.

Entities:  

Mesh:

Year:  2009        PMID: 20019161      PMCID: PMC2835443          DOI: 10.1124/jpet.109.162651

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  33 in total

Review 1.  Effect of alcohol consumption on the gut.

Authors:  Christiane Bode; J Christian Bode
Journal:  Best Pract Res Clin Gastroenterol       Date:  2003-08       Impact factor: 3.043

2.  Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy?

Authors:  John P Buchweitz; Patricia E Ganey; Steven J Bursian; Robert A Roth
Journal:  J Pharmacol Exp Ther       Date:  2002-02       Impact factor: 4.030

3.  Effects of ethanol dose and ethanol withdrawal on rat liver mitochondrial glutathione: implication of potentiated acetaminophen toxicity in alcoholics.

Authors:  Ping Zhao; John T Slattery
Journal:  Drug Metab Dispos       Date:  2002-12       Impact factor: 3.922

4.  Drug enterocyte adducts: possible causal factor for diclofenac enteropathy in rats.

Authors:  C R Atchison; A B West; A Balakumaran; S J Hargus; L R Pohl; D H Daiker; J F Aronson; W E Hoffmann; B K Shipp; M Treinen-Moslen
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

Review 5.  Adverse reactions to fluoroquinolones. an overview on mechanistic aspects.

Authors:  A De Sarro; G De Sarro
Journal:  Curr Med Chem       Date:  2001-03       Impact factor: 4.530

6.  Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data.

Authors:  S C Lewis; M J S Langman; Joan-Ramon Laporte; John N S Matthews; Michael D Rawlins; Bengt-Erik Wiholm
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

7.  Bacterial- and viral-induced inflammation increases sensitivity to acetaminophen hepatotoxicity.

Authors:  Jane F Maddox; Chidozie J Amuzie; Maoxiang Li; Sandra W Newport; Erica Sparkenbaugh; Christopher F Cuff; James J Pestka; Glenn H Cantor; Robert A Roth; Patricia E Ganey
Journal:  J Toxicol Environ Health A       Date:  2010

Review 8.  Hepatocellular damage from non-steroidal anti-inflammatory drugs.

Authors:  N O'Connor; P I Dargan; A L Jones
Journal:  QJM       Date:  2003-11

Review 9.  Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity.

Authors:  Urs A Boelsterli
Journal:  Toxicol Appl Pharmacol       Date:  2003-11-01       Impact factor: 4.219

10.  Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats.

Authors:  James P Luyendyk; Jane F Maddox; Gregory N Cosma; Patricia E Ganey; Gary L Cockerell; Robert A Roth
Journal:  J Pharmacol Exp Ther       Date:  2003-07-31       Impact factor: 4.030

View more
  39 in total

Review 1.  Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity.

Authors:  Patrick J Shaw; Patricia E Ganey; Robert A Roth
Journal:  Toxicol Sci       Date:  2010-06-10       Impact factor: 4.849

Review 2.  In vitro platforms for evaluating liver toxicity.

Authors:  Shyam Sundhar Bale; Lawrence Vernetti; Nina Senutovitch; Rohit Jindal; Manjunath Hegde; Albert Gough; William J McCarty; Ahmet Bakan; Abhinav Bhushan; Tong Ying Shun; Inna Golberg; Richard DeBiasio; Berk Osman Usta; D Lansing Taylor; Martin L Yarmush
Journal:  Exp Biol Med (Maywood)       Date:  2014-04-24

3.  Metabolite profiling and pharmacokinetic evaluation of hydrocortisone in a perfused three-dimensional human liver bioreactor.

Authors:  Ujjal Sarkar; Dinelia Rivera-Burgos; Emma M Large; David J Hughes; Kodihalli C Ravindra; Rachel L Dyer; Mohammad R Ebrahimkhani; John S Wishnok; Linda G Griffith; Steven R Tannenbaum
Journal:  Drug Metab Dispos       Date:  2015-04-29       Impact factor: 3.922

4.  Microengineered cell and tissue systems for drug screening and toxicology applications: Evolution of in-vitro liver technologies.

Authors:  O B Usta; W J McCarty; S Bale; M Hegde; R Jindal; A Bhushan; I Golberg; M L Yarmush
Journal:  Technology (Singap World Sci)       Date:  2015-03

Review 5.  Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors.

Authors:  Emanuel Raschi; Fabrizio De Ponti
Journal:  Front Pharmacol       Date:  2019-10-24       Impact factor: 5.810

Review 6.  Opportunities and challenges in the wider adoption of liver and interconnected microphysiological systems.

Authors:  David J Hughes; Tomasz Kostrzewski; Emma L Sceats
Journal:  Exp Biol Med (Maywood)       Date:  2017-05-15

Review 7.  An overview on the proposed mechanisms of antithyroid drugs-induced liver injury.

Authors:  Reza Heidari; Hossein Niknahad; Akram Jamshidzadeh; Mohammad Ali Eghbal; Narges Abdoli
Journal:  Adv Pharm Bull       Date:  2015-03-05

Review 8.  Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria.

Authors:  Derick Han; Lily Dara; Sanda Win; Tin Aung Than; Liyun Yuan; Sadeea Q Abbasi; Zhang-Xu Liu; Neil Kaplowitz
Journal:  Trends Pharmacol Sci       Date:  2013-02-28       Impact factor: 14.819

9.  Acetaminophen-induced acute liver injury in HCV transgenic mice.

Authors:  Takeki Uehara; Oksana Kosyk; Emmanuelle Jeannot; Blair U Bradford; Katherine Tech; Jeffrey M Macdonald; Gary A Boorman; Saurabh Chatterjee; Ronald P Mason; Stepan B Melnyk; Volodymyr P Tryndyak; Igor P Pogribny; Ivan Rusyn
Journal:  Toxicol Appl Pharmacol       Date:  2012-11-29       Impact factor: 4.219

Review 10.  Drug-induced liver injury in older adults.

Authors:  Sarah J Mitchell; Sarah N Hilmer
Journal:  Ther Adv Drug Saf       Date:  2010-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.